EDWARDS Christine (GB),ЭДУАРДС Кристин (GB),KULAGOWSKI Janusz (GB),КУЛАГОВСКИ Януш (GB),FINCH Harry (GB),ФИНЧ Гарри (GB),EDWARDS CHRISTINE,ЭДУАРДС Кристин,KULAGOWSKI JANUSZ,КУЛАГОВСКИ Януш,FINCH HARRY,ФИНЧ Гарри
申请号：
RU2012138579/04
公开号：
RU0002581839C2
申请日:
2011.03.10
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of formula (I) or their pharmaceutically acceptable salt, which are neutrophil elastase (hNE) inhibitors. The compounds can be applicable for treating a disease or condition, which involves hNE, or in producing a medicinal agent. This disease or condition can be presented by chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, emphysema caused by smoking, or mucoviscidosis, asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, nonspecific ulcerative colitis or irritable bowel disease. In formula (I),A represents C-R1； R1 and R2 represent hydrogen； R4 represents hydrogen； R3 and R5 are independently specified in hydrogen and C1-C6-alkyl, which can be additionally substituted by halogen； R6 represents -CO2R11； -X1-X2- represents -NR19-CO-； R11 represents a radical of formula -[Alk1]p-[Alk2]q-Z, wherein p and q independently mean 0 or 1 provided, p and q does not mean 0 at the same time； each Alk1 and Alk2 independently represent C1-C6-alkylene radical； Z represents (1) -N(RA)(RB), wherein RA and RB independently represent hydrogen or C1-C6-alkyl group； or (2) -N+(RA)(RB)(RC), wherein RA, RB and RC independently represent C1-C6-alkyl group； R19 is specified in hydrogen and (C1-C6)alkyl； optionally in the form of a pharmaceutically acceptable salt.EFFECT: compounds can be applicable for treating a disease or condition, which involves hNE, or in producing a medicinal agent.14 cl, 3 exИзобретение относится к новым соединениям формулы (I) или их фармацевтически приемлемой соли, которые являются ингибиторами нейтрофильной эластазы (HNE). Соединения могут быть использованы для лечения заболевания или состояния, в которое вовлечена HNE, или для применения в изготовлении лекарственного средства. Таким заболеванием или состоянием может быть хроническое обструкт
